Kevin Schwartzman


Kevin Schwartzman MD, MPH, FRCPC
Professor of Medicine
Director, Respiratory Division
McGill University and McGill University Health Centre
Centre for Outcomes Research and Evaluation
Research Institute of the McGill University Health Centre
5252 boul. de Maisonneuve O., Room 3D.63
Montréal, Québec H4A 3S5 CANADA

Phone:  514-934-1934, extensions 32560/32153
Fax:  514-843-2083
kevin.schwartzman [at]



Research focuses on the clinical and economic evaluation of interventions in tuberculosis and other respiratory diseases, including screening and treatment for TB infection, and the application of digital technologies to TB care.


tuberculosis, epidemiology, public health, quality of life, cost-effectiveness, digital adherence technologies 

Selected Publications

Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, Ferreira E, Melgen RE, Morose W, Cruz Salgado A, Jacquet V, Maloney S, Laserson K, Pablos-Mendez A, Menzies D.  Domestic returns from investment in the control of tuberculosis in other countries.  N Engl J Med2005; 353:1008-20.

Bauer M, Ahmed S, Benedetti A, Greenaway C, Lalli M, Leavens A, Menzies D, Vadeboncoeur C, Vissandjee B, Wynne A, Schwartzman K.  The impact of tuberculosis on health utility:  A longitudinal cohort study.  Quality of Life Research. 2015 Jun; 24(6):1337-1349.

Mullie GA, Schwartzman K, Zwerling A, N’Diaye DS.  Revisiting screening for latent tuberculosis infection in health care workers:  A cost-effectiveness analysis.  BMC Medicine; 2017; 15:104.

Cormier M, Schwartzman K, N'Diaye DS, Boone CE, dos Santos AM, Gaspar J, Cazabon D, Ghiasi M, Kahn R, Uppal A, Morris M, Oxlade O.  Proximate determinants of tuberculosis in Indigenous peoples worldwide: a systematic review. Lancet Global Health 2019; 7: e68-80.

Nsengiyumva NP, Mappin-Kasirer B, Oxlade O, Bastos M, Trajman A, Falzon D, Schwartzman K.  Evaluating the potential costs and impacts of digital health technologies for tuberculosis treatment support.  European Respiratory Journal 2018; 52: 1801363

N’Diaye DS, Nsengiyumva NP, Uppal A, Oxlade O, Alvarez GG, Schwartzman K.  The potential impact and cost-effectiveness of tobacco reduction strategies for tuberculosis prevention in Canadian Inuit communities.  BMC Medicine 2019; 17: 26.

Uppal A, Nsengiyumva NP, Signor C, Jean-Louis F, Rochette M, Snowball H, Etok S, Annanack D, Ikey J, Ahmad Khan F, Schwartzman K. Active screening for tuberculosis in high-incidence Inuit communities in Canada: a cost-effectiveness analysis.  CMAJ 2021; 193: E1652-9.

Nsengiyumva NP, Campbell JR, Oxlade O, Vesga JF, Lienhardt C, Trajman A, Falzon D, Den Boon S, Arinaminpathy N, Schwartzman K.  Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness.  PLOS Medicine 2022; 19(6):e1004032.  PMID: 35696431

External Links

Follow on PubMed 


Back to top